Rubio-Martínez Luis M, Elmas Colette R, Black Belinda, Monteith Gabrielle
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Canada.
J Am Vet Med Assoc. 2012 Dec 15;241(12):1650-8. doi: 10.2460/javma.241.12.1650.
To describe the clinical use of regional limb perfusion with antimicrobials (A-RLP), complications, and outcome in a large series of patients.
Retrospective case series.
174 horses.
Medical records of horses treated with A-RLP between 1999 and 2009 were reviewed. Signalment, primary complaint, horse use, etiology, duration of clinical signs, previous treatment, structures involved, concurrent conditions, A-RLP characteristics, additional treatments, complications, and outcome were recorded. At long-term follow-up, 2 outcomes were investigated: survival rate and return to previous use at the same or higher level. Univariate and multivariate logistic regression analyses were conducted.
Group 1 (96 horses) included septic synovitis. Group 2 (50 horses) included extrasynovial lacerations (23 horses) and fresh, minimally contaminated intrasynovial lacerations without evidence of established synovial infection (27 horses). Group 3 (28 horses) included miscellaneous other conditions. Only minor complications were reported in 12.26% of horses that received IV (n = 155) and 33% of horses that received intraosseous (27) A-RLP. Horses with septic synovitis had a lower survival rate (53.43%) than did horses with lacerations (91.89%). Within group 2, no significant differences in short- or long-term outcomes were found between horses with extrasynovial and fresh, minimally contaminated intrasynovial lacerations. For the horses returning to previous use, 80% of horses with septic synovitis and 72.72% of horses with lacerations were performing at the same or higher level at the time of follow-up.
The results of the present study indicated that A-RLP is a safe technique with minimal adverse effects. The IV route presented fewer complications than intraosseous injection. Horses with infection of synovial structures had a lower survival rate than did those with acute, minimally contaminated intrasynovial lacerations. The latter had a similar prognosis for horses with extrasynovial lacerations treated with A-RLP.
描述大量患者中抗菌药物区域肢体灌注(A-RLP)的临床应用、并发症及结果。
回顾性病例系列研究。
174匹马。
回顾1999年至2009年间接受A-RLP治疗的马匹的病历。记录马匹的特征、主要诉求、用途、病因、临床症状持续时间、既往治疗情况、受累结构、并发疾病、A-RLP特点、额外治疗、并发症及结果。在长期随访中,调查了两个结果:生存率以及恢复到之前相同或更高水平的使用情况。进行了单因素和多因素逻辑回归分析。
第1组(96匹马)包括化脓性滑膜炎。第2组(50匹马)包括滑膜外裂伤(23匹马)和新鲜的、污染轻微的滑膜内裂伤且无已确诊的滑膜感染证据(27匹马)。第3组(28匹马)包括其他各种情况。接受静脉注射(n = 155)的马匹中有12.26%以及接受骨内注射(27匹)的马匹中有33%仅报告有轻微并发症。化脓性滑膜炎的马匹生存率(53.43%)低于裂伤的马匹(91.89%)。在第2组中,滑膜外裂伤和新鲜的、污染轻微的滑膜内裂伤的马匹在短期或长期结果方面未发现显著差异。对于恢复到之前使用水平的马匹,化脓性滑膜炎的马匹中有80%以及裂伤的马匹中有72.72%在随访时处于相同或更高水平。
本研究结果表明A-RLP是一种安全的技术,不良反应最小。静脉注射途径比骨内注射并发症更少。滑膜结构感染的马匹生存率低于急性、污染轻微的滑膜内裂伤的马匹。后者与接受A-RLP治疗的滑膜外裂伤的马匹预后相似。